Ionis Pharmaceuticals Shares Drop Amid Failed Clinical Trial and Roche Partnership Exit

Ionis Pharmaceuticals (IONS) experienced a significant stock decline after its heart drug Wainua failed to meet primary goals in a late-stage trial. The setback was compounded when partner Roche ended two Huntington's disease programs with Ionis, leading to further losses.

By Peace Longe Sun, July 12, 2026 at 7:17 PM GMT+3 4 min read · Yahoo Finance · July 12, 2026, 16:17 UTC

Tickers: $AZN $IONS

Topics: clinical trial failure pipeline setbacks stock crash

Read the full article at Yahoo Finance

More Health news

Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC
Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths Seeking Alpha · October 29, 2026, 16:18 UTC